Monday, November 23,  5:53 am

Forward-looking intelligence allows you time to act. View this video on our restructuring content to see how you can benefit from our expertise.

Cerberus Capital Management LP and Ampersand Ventures' $3.1 billion sale of blood plasma group Talecris Biotherapeutics Inc. to Australia's CSL Ltd. looks likely to collapse because of opposition from U.S. regulators.

CSL said Monday that the Federal Trade Commission had told managing director Brian McNamee that it would recommend the deal be blocked.

This is a free preview of the content available in The Deal Pipeline. Subscribers enjoy access to the full story, as well as second-to-none research tools.

To request a demo, or, if you are an existing user to The Deal Pipeline, log in to your account, please scroll down and click the button.

Dig deeper, with Pipeline.

• 806 in-depth reports of M&A deals in the Healthcare sector
• 72 articles related to CSL Ltd.
• 10 in-depth reports of PE deals in the Healthcare sector
• 9 articles related to Talecris Biotherapeutics
• 10 years of news and analysis archives from the voice of The Deal Economy
  

Most searched keywords

• Deutsche Bank
• Birds Eye
• Cadbury AG
  
• Agrium Inc.
• Skadden Arps
• Revolution Money
• Tandberg ASA
• Aisling Capital
  
• Ken Lewis
  
• Natco